Acurx Pharmaceuticals (ACXP) Retained Earnings (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Retained Earnings came in at $84.0 million in Q1 2026, up 17.03% YoY from $71.8 million in Q1 2025, and up 4.25% on a QoQ basis from $80.6 million in Q4 2025.
Acurx Pharmaceuticals (ACXP) Retained Earnings (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Retained Earnings data on file, last reported at $84.0 million in Q1 2026.
- Quarterly Retained Earnings rose 17.03% year-over-year to $84.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.0 million (up 17.03% YoY) and the FY2025 annual result came in at $80.6 million, up 219.66% from the prior year.
- Retained Earnings grew to $84.0 million in Q1 2026, from $80.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $84.0 million in Q1 2026 to a low of -$73.7 million in Q3 2025.
- A 5-year average of $1.7 million and a median of -$31.8 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 260.79% — and 2024, when it tumbled 222.95%.
- Tracing ACXP's Retained Earnings over 5 years: stood at -$38.6 million in 2022, then tumbled by 37.73% to -$53.2 million in 2023, then slipped by 26.5% to -$67.3 million in 2024, then surged by 219.66% to $80.6 million in 2025, then advanced by 4.25% to $84.0 million in 2026.
- The last three Retained Earnings figures came in at $84.0 million (Q1 2026), $80.6 million (Q4 2025), and -$73.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | 87.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.37 Mn |
| Mar 31, 2026 | 83.98 Mn |
| Dec 31, 2025 | 80.55 Mn |
| Sep 30, 2025 | -73.71 Mn |
| Jun 30, 2025 | -71.72 Mn |
| Mar 31, 2025 | 71.76 Mn |
| Dec 31, 2024 | -67.32 Mn |
| Sep 30, 2024 | 67.19 Mn |
| Jun 30, 2024 | 65.13 Mn |
| Mar 31, 2024 | -57.60 Mn |
| Dec 31, 2023 | -53.22 Mn |
| Sep 30, 2023 | -48.10 Mn |
| Jun 30, 2023 | 51.19 Mn |
| Mar 31, 2023 | 46.84 Mn |
| Dec 31, 2022 | -38.64 Mn |
| Sep 30, 2022 | -35.38 Mn |
| Jun 30, 2022 | -31.84 Mn |
| Mar 31, 2022 | 39.90 Mn |
| Dec 31, 2021 | 38.95 Mn |
| Sep 30, 2021 | -23.92 Mn |